THYROID ASSOCIATED OPHTHALMOPATHIES
Clinical trials for THYROID ASSOCIATED OPHTHALMOPATHIES explained in plain language.
Never miss a new study
Get alerted when new THYROID ASSOCIATED OPHTHALMOPATHIES trials appear
Sign up with your email to follow new studies for THYROID ASSOCIATED OPHTHALMOPATHIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug could ease bulging eyes in thyroid disease
Disease control Recruiting nowThis study tests a new medicine called MHB018A for people with active moderate-to-severe thyroid eye disease, which causes bulging eyes and discomfort. About 108 adults aged 18-75 will receive either the drug or a placebo every 4 weeks for 6 months. The main goal is to see if the…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated May 26, 2026 11:59 UTC
-
New hope for thyroid eye disease: drug targets bulging eyes and double vision
Disease control Recruiting nowThis study tests a drug called IBI311 in 50 adults with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. The drug works by blocking a specific receptor to reduce swelling and tissue growth behind the eyes. Researchers wil…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
New drug IBI311 takes on steroids in battle for thyroid eye disease relief
Disease control Recruiting nowThis study tests two treatments for active moderate to severe thyroid eye disease (TAO), a condition that can cause bulging eyes, double vision, and even blindness. One group gets standard hormone therapy, the other gets IBI311, a newer targeted drug. Researchers will compare how…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New antibody therapy offers hope for thyroid eye disease patients who failed steroids
Disease control Recruiting nowThis study tests a drug called tetuzumab (IBI311) in 96 adults with moderate-to-severe active thyroid eye disease (TAO) who did not respond well to steroids. The drug blocks a protein that fuels inflammation and tissue swelling behind the eyes. The main goals are to see if it red…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Can eye tracking reveal hidden impacts of thyroid eye disease?
Knowledge-focused Recruiting nowThis study uses a non-invasive eye-tracking test to understand how Thyroid-Associated Ophthalmopathy (TAO) affects eye movement and visual attention. Researchers will compare 100 participants, including both patients and healthy volunteers, to measure differences in gaze stabilit…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Sponsor: Shanghai Changzheng Hospital • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC